Trials / Active Not Recruiting
Active Not RecruitingNCT04017455
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Detailed description
38 patients with resectable rectal cancer will be enrolled. All patients will be treated with radiotherapy followed by bevacizumab and atezolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | 3 cycles of atezolizumab 840 mg |
| DRUG | Bevacizumab | 3 cycles of bevacizumab 5mg/kg |
Timeline
- Start date
- 2019-10-22
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
- First posted
- 2019-07-12
- Last updated
- 2025-06-08
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04017455. Inclusion in this directory is not an endorsement.